

# Caribbean Dermatology 2018 - NEEDS ASSESSMENTS AND GAPS

## ACNE

### REFERENCES

- Bowe WP. Antibiotic resistance and acne: where we stand and what the future holds. *J Drugs Dermatol*. 2014;13:s66-70.
- Cook-Bolden FE. Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris. *J Clin Aesthet Dermatol*. 2015;8:28-32.
- Del Rosso JQ. The changing face of challenges in the management of acne and rosacea. *J Drugs Dermatol*. 2014;13:649.
- Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. *Pediatrics*. 2013;131:S163-186.
- Hsu P, Litman GI, Brodell RT. Overview of the treatment of acne vulgaris with topical retinoids. *Postgrad Med*. 2011;123:153-161.
- Jarratt MT, Brundage T. Efficacy and safety of clindamycin-tretinoin gel versus clindamycin or tretinoin alone in acne vulgaris: a randomized, double-blind, vehicle-controlled study. *J Drugs Dermatol*. 2012;11:318-826.
- Momen S, Al-Niaimi F. Acne vulgaris and light-based therapies. *J Cosmet Laser Ther*. 2015;17:122-128.
- Pruthi GK, Babu N. Physical and psychosocial impact of acne in adult females. *Indian J Dermatol*. 2012;57:26-29.
- Skolnik N, Lee A. Diagnosis and treatment of pediatric acne. *Skin & Allergy News*. July 1 2013.
- Stein Gold LF. What's new in acne and inflammation? *J Drugs Dermatol*. 2013;12:s67-69.
- Tan J, Gollnick HP, Loesche C, Ma YM, Gold LS. Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients. *J Dermatolog Treat*. 2011;22:197-205.
- Zaenglein AL, Pathy AL, Schlosser BJ, et al, for the Work Group: Guidelines of care for the management of acne vulgaris. *J Am Acad Dermatol*. 2016;74:945-973.

## ATOPIC DERMATITIS

### REFERENCES

- Eichenfield LF et al. Translating Atopic Dermatitis Management Guidelines Into Practice for Primary Care Providers. [Pediatrics](#). 2015 Sep;136(3):554-65. doi: 10.1542/peds.2014-3678. Epub 2015 Aug 3.
- Hilton L. Dupilumab demonstrates promising results. *Dermatology Times*. July 15, 2016. <http://dermatologytimes.modernmedicine.com/dermatology-times/news/dupilumab-demonstrates-promising-results>. Accessed August 1, 2016.
- Hilton L. Investigative eczema drug shows positive phase 2 results. *Dermatology Times*. July 15, 2016. <http://dermatologytimes.modernmedicine.com/dermatology-times/news/investigative-eczema-drug-shows-positive-phase-2-results>. Accessed August 1, 2016.
- Afshar M, Kotol P, Miller J, Gallo R, Hata T. The effect of pimecrolimus on innate immunity in atopic dermatitis subjects: a double-blind, randomized, vehicle-controlled study. *Br J Dermatol*. 2013;168:426-428.
- Gallo RL, Nakatsuji T. Microbial symbiosis with the innate immune defense system of the skin. *J Invest Dermatol*. 2011;131:1974-1980.
- Garmhausen D, Hagemann T, Bieber T, Dimitriou I, Fimmers R, Diepgen T, et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. *Allergy*. 2013;68(4):498-506.

Garnacho-Saucedo G, Salido-Vallejo R, Moreno-Giménez JC. Atopic dermatitis: update and proposed management algorithm. *Actas Dermosifiliogr*. 2013;104:4-16.

Hamilton JD, Suárez-Fariñas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. *J Allergy Clin Immunol*. 2014 Dec;134(6):1293-300.

Hanifin J et al. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study. *J Am Acad Dermatol*. 2016 Aug;75(2):297-305. doi: 10.1016/j.jaad.2016.04.001. Epub 2016 May 14

Hon KL, Leung AK, Barankin B. Barrier repair therapy in atopic dermatitis: an overview. *Am J Clin Dermatol*. 2013;14:389-399.

Kong H, Segre JA. Skin microbiome: Looking back to move forward. *J Invest Dermatol*. 2012;132:933-939.

Leung DYM, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. *J Clin Invest*. 2004;113:651-657.

Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. *Cytokine*. 2015 Jun;73(2):311-318.

Miyagaki T, Sugaya M. Recent advances in atopic dermatitis and psoriasis: genetic background, barrier function, and therapeutic targets. *J Dermatol Sci*. 2015;78:89-94.

Niebuhr M, Werfel T. Innate immunity, allergy and atopic dermatitis. *Curr Opin Allergy Clin Immunol*. 2010;10:463-468.

O'Toole A, Thomas B, Thomas R. The care triangle: determining the gaps in the management of atopic dermatitis. *J Cutan Med Surg*. 2013;17:276-282.

Paller AS et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. *J Am Acad Dermatol*. 2016 Jul 7. pii: S0190-9622(16)30330-9. doi: 10.1016/j.jaad.2016.05.046. [Epub ahead of print]

Simpson EL et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). *J Am Acad Dermatol*. 2016 Jun 4. pii: S0190-9622(16)30193-1. doi: 10.1016/j.jaad.2016.04.054. [Epub ahead of print]

## **CONTACT DERMATITIS**

### **REFERENCES**

Becker D. Allergic contact dermatitis. *J Dtsch Dermatol Ges*. 2013;11:607-621.

Cashman MW, Reutemann PA, Ehrlich A. Contact dermatitis in the United States: epidemiology, economic impact, and workplace prevention. *Dermatol Clin*. 2012;30:87-98.

Callahan A, Baron E, Fekedulegn D, et al. Winter season, frequent hand washing, and irritant patch test reactions to detergents are associated with hand dermatitis in health care workers. *Dermatitis*. 2013;24:170-175.

Fonacier LS, Aquino MR, Mucci T. Current strategies in treating severe contact dermatitis in pediatric patients. *Curr Allergy Asthma Rep*. 2012;12:599-606.

Fonacier L, Bernstein DI, Pacheco K, et al. Contact dermatitis: a practice parameter—Update 2015. *J Allergy Clin Immunol Pract*. 2015;3:S1-S39.

King I, Nicholson P. Getting a grip on guidelines: occupational contact dermatitis and urticaria. *Br J Gen Pract*. 2010;60:398-399.

Smedley J; OHCEU Dermatitis Group; BOHRF Dermatitis Group. Concise guidance: diagnosis, management and prevention of occupational contact dermatitis. *Clin Med*. 2010;10:487-490.

## **CUTANEOUS CANCER: ACTINIC KERATOSIS**

### **REFERENCES**

Bagazgoitia L, Cuevas J, Juarranz A. Expression of p53 and p16 in actinic keratosis, bowenoid actinic keratosis and Bowen's disease. *J Eur Acad Dermatol Venereol*. 2010;24:228-230.

Del Rosso JQ. Current regimens and guideline implications for the treatment of actinic keratosis: proceedings of a clinical roundtable at the 2011 Winter Clinical Dermatology Conference. *Cutis*. 2011;88(suppl):S1-S8.

Lewis CM, Glisson BS, Feng L, et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. *Clin Cancer Res*. 2012;18:1435-1446.

Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. *Nat Clin Pract Oncol*. 2007;4:462-469.

Ra SH, Li X, Binder S. Molecular discrimination of cutaneous squamous cell carcinoma from actinic keratosis and normal skin. *Mod Pathol*. 2011;24:963-973.

Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. *J Am Acad Dermatol*. 2012;66:486-493.

Samrao A, Cockerell CJ. Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents. *Am J Clin Dermatol*. 2013;14:273-277.

Schäfer-Korting M; Höltje M; Korting HC; Höltje HD. Innovative agents for actinic keratosis and nanocarriers enhancing skin penetration. *Skin Pharmacol Physiol*. 2010;23:6-14.

Soyer HP, Prow TW, Jemec GBE. Actinic keratosis. *Curr Probl Dermatol*. 2015;46:143-149.

Stahlhut M, Chahal H, Lord J, et al. Ingenol mebutate initiates multiple specific cell death pathways in human cancer cells. *J Am Acad Dermatol*. 2012;66(4suppl1):AB152.

Stockfleth E. The paradigm shift in treating actinic keratosis: a comprehensive strategy. *J Drugs Dermatol*. 2012;11:1462-1467.

## **CUTANEOUS CANCER: MELANOMA**

### **REFERENCES**

America Cancer Society: Cancer Facts and Figures 2013.

<http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013> Accessed August 9, 2016.

Chapman PB, Hauschild A, Robert C, et al. The improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med*. 2011;364:2507-2516.

Dharmadhikari N, Mehnert JM, Kaufman HL. Oncolytic virus immunotherapy for melanoma. *Curr Treat Options Oncol*. 2015;16:326.

Luke JJ, Hodi FS. Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. *Clin Cancer Res*. 2012;18:9-14.

Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. *Lancet Oncol*. 2012;13:459-465.

Menzies AM, Long GV. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. *Clin Cancer Res*. 2014;20:2035-2043.

Metastatic Melanoma Sees Huge Gains in Therapies, and Costs, Within Last Two Years, *Specialty Pharmacy News*. 2013;Vol 10.

National Cancer Institute at the National Institutes of Health.

<http://www.cancer.gov/cancertopics/pdq/treatment/melanoma/HealthProfessional>. Updated April 15, 2016 Accessed August 9, 2016.

Page DB, Yuan J, Wolchok JD. Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers. *Immunotherapy*. 2010;2:367-379.

Richman J, Martin-Liberal J, Diem S, Larkin J. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. *Expert Opin Pharmacother*. 2015;16:1285-1297.

SEER Stat Fact Sheets: Melanoma of the Skin. <http://seer.cancer.gov/statfacts/html/melan.html> Accessed August 9, 2016.

von Thaler AK, Kamenisch Y, Berneburg M. The role of ultraviolet radiation in melanomagenesis. *Exp Dermatol*. 2010;19:81-88.

Wolchok JD, Yang AS, Weber JS. Immune regulatory antibodies: are they the next advance? *Cancer J*. 2010;16:311-317.

## **CUTANEOUS MANIFESTATIONS OF COMMON SYSTEMIC DISEASES**

### **REFERENCES**

Grandinetti LM, Tomecki KJ. Dermatologic signs of systemic disease.

<http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/dermatology/dermatologic-signs-of-systemic-disease/> Accessed August 8, 2016.

Lebwohl M. *The Skin and Systemic Disease: A Color Atlas and Text*. Second edition. New York, NY: Churchill Livingstone, 2004.

Wong HK. Urticaria. <http://emedicine.medscape.com/article/762917-overview> Accessed August 9, 2016.

## **DERMOSCOPY**

### **REFERENCES**

Argenziano G, Cerroni L, Zalaudek I, et al. Accuracy in melanoma detection: a 10-year multicenter survey. *J Am Acad Dermatol*. 2011;67:54.e1-59.e1.

Errichetti E, Stinco G. The practical usefulness of dermoscopy in general dermatology. *Ital Dermatol Venereol*. 2015;150:533-546.

Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. *Lancet Oncol*. 2002;3:159-165.

Lallas A, Apalla Z, Chaidemenos G. New trends in dermoscopy to minimize the risk of missing melanoma. *J Skin Cancer*. 2012;2012:820474.

## **ONYCHOMYCOSIS**

### **REFERENCES**

Becker C, Bershaw A. Lasers and photodynamic therapy in the treatment of onychomycosis: a review of the literature. *Dermatol Online J*. 2013;19:19611.

Carney C, Cantrell W, Warner J, Elewski B. Treatment of onychomycosis using a submillisecond 1064-nm neodymium:yttrium-aluminum-garnet laser. *J Am Acad Dermatol*. 2013;69:578-582.

Gazes MI, Zeichner J. Onychomycosis in close quarter living review of the literature. *Mycoses*. 2013;56:610-613.

Ghannoum M, Isham N, Catalano V. A second look at efficacy criteria for onychomycosis: clinical and mycological cure. *Br J Dermatol*. 2014;170:182-187.

Ghannoum MA, Mukherjee PK, Warshaw EM, Evans S, Korman NJ, Tavakkol A. Molecular analysis of dermatophytes suggests spread of infection among household members. *Cutis*. 2013;91:237-245.

Gilaberte Y, Aspiroz C, Martes MP, Calcade V, Espinel-Ingroff A, Reszuta A. Treatment of refractory fingernail onychomycosis caused by nondermatophyte molds with methylaminolevulinate photodynamic therapy. *J Am Acad Dermatol*. 2011;65:669-671.

Gupta AK, Simpson F. Newly approved laser systems for onychomycosis. *J Am Podiatr Med Assoc*. 2012;102:428-430.

Gupta AK, Simpson FC. Investigational drugs for onychomycosis. *Expert Opin Investig Drugs*. 2014;23:97-106.

Hafeez F, Hui X, Chiang A, Hornby S, Maibach H. Transungual delivery of ketoconazole using novel lacquer formulation. *Int J Pharm*. 2013;456:357-361.

Jarratt M, Siu WJ, Yamakawa E, Kodera N, Pillai R, Smith K. Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis: low systemic exposure suggests remote drug-drug interaction potential. *J Drugs Dermatol*. 2013;12:1010-1016.

Klaassen KM, Dulak MG, van de Kerkhof PC, Pasch MC. The prevalence of onychomycosis in psoriatic patients: a systematic review. *J Eur Acad Dermatol Venereol*. 2014;28:533-541.

Rosen T, Friedlander SF, Kircik L, et al. Onychomycosis: epidemiology, diagnosis, and treatment in a changing landscape. *J Drugs Dermatol*. 2015;14:223-233.

Scher RK, Nakamura N, Tavakkol A. Luliconazole: a review of a new antifungal agent for the topical treatment of onychomycosis. *Mycoses*. 2014;57:389-393.

## **PSORIASIS**

### **REFERENCES**

Sonnenreich MA. Advances in psoriasis treatment: experts comment on recent developments. *P&T*. 2013;38:12.

Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: A phase 3 randomised non-inferiority trial. *Lancet*. 2015;386:552-561.

Bissonnette R, Papp K, Maari C, et al. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon- $\alpha$  monoclonal antibody, in subjects with chronic psoriasis. *J Am Acad Dermatol*. 2010;62:427-436.

Chan SA, Hussain F, Lawson LG, Ormerod AD. Factors affecting adherence to treatment of psoriasis: Comparing biologic therapy to other modalities. *J Dermatolog Treat*. 2011 Sep 7. [Epub ahead of print]

de Jager MEA, de Jong EMGJ, van de Kerhjoef PCM, Seyger MMB. Efficacy and safety of treatments for childhood psoriasis: A systematic literature review. *J Am Acad Dermatol*. 2010;62:1013-1030.

Gordon KB, Papp KA, Langley RG, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials. *J Am Acad Dermatol*. 2012;66(5):742-751.

Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. *N Engl J Med*. 2015;373:136-144.

Gottlieb AB, Gordon K, Giannini EH, et al. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. *J Drugs Dermatol*. 2011;10:289-300.

Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials. *Lancet*. 2015;386:541-551.

Kurzeja M, Rudnicka L, Olszewska M. New interleukin-23 pathway inhibitors in dermatology: Ustekinumab, briakinumab, and secukinumab. *Am J Clin Dermatol*. 2011;12:113-125.

- Kwon HH, Na SJ, Jo SJ, Youn JI. Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic. *J Dermatol*. 2012;39:260-264.
- Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—Results of two phase 3 trials. *N Engl J Med*. 2014;371:326-338.
- McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. *Lancet*. 2013;382:780-789.
- Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. *J Am Acad Dermatol*. 2010;63:448-456.
- Mrowietz U. Implementing treatment goals for successful long-term management of psoriasis. *J Eur Acad Dermatol Venereol*. 2012;26(Suppl 2):12-20.
- O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. *Ann Rheum Dis*. 2013;72(suppl 2):ii111-115.
- Paller AS, Siegfried EC, Pariser DM, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. *J Am Acad Dermatol*. 2016;74:280-287.e3.
- Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: A phase III, randomized controlled trial (ESTEEM 2). *Br J Dermatol*. 2015;173:1387-1399.
- Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: A meta-analysis of randomized controlled trials. *JAMA*. 2011;306:864-871.
- Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. *BMJ*. 2010;340:c147.